Jason Karlawish

BioTech

Dementia risk, higher than thought, requires a national strategy

A recent Nature Medicine research report is sounding an alarm. The risk of developing dementia by the age of 95 is 42%. The finding that

Jason Karlawish January 18, 2025

BioTech

Aduhelm was a mess — and it could happen again

Last week, Biogen announced it will cease both the study and sale of Aduhelm, its FDA-approved monoclonal antibody for the treatment of Alzheimer’s disease. Its

Jason Karlawish February 6, 2024

BioTech

The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab

Over the past several months, my conversations with colleagues in the Alzheimer’s field have featured an unusual sentiment: optimism inflected with worry. Optimism because, after

Jason Karlawish June 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Jason Karlawish

Dementia risk, higher than thought, requires a national strategy

Aduhelm was a mess — and it could happen again

The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe